Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily | Zendy

Reshma Autar | Zendy; Jintanat Ananworanich | Zendy; W. Apateerapong | Zendy; Jongkol Sankote | Zendy; Andrew Hill | Zendy; Bernard Hirschel | Zendy; David A. Cooper | Zendy; J Lange | Zendy; Praphan Phanuphak | Zendy; Kiat Ruxrungtham | Zendy; Danielle Burger | Zendy

Open Access

Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily

Author(s) -

Reshma Autar,

Jintanat Ananworanich,

W. Apateerapong,

Jongkol Sankote,

Andrew Hill,

Bernard Hirschel,

David A. Cooper,

J Lange,

Praphan Phanuphak,

Kiat Ruxrungtham,

Danielle Burger

Publication year - 2004

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkh415

Subject(s) - cmin , saquinavir , ritonavir , cmax , pharmacokinetics , pharmacology , dosing , medicine , dose , human immunodeficiency virus (hiv) , virology , viral load , antiretroviral therapy

A pharmacokinetic comparison of three dosing regimens of saquinavir/ritonavir was carried out: 1600/100 mg once-daily with 1000/100 mg twice-daily, and 1600/100 mg once-daily with 2000/100 mg once-daily.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research